Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06775379 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06775379 · ClinicalTrials.gov record · last posted 2026-08-03

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

Name: A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder — clinical trial record (NCT06775379)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: X-NOVA2

StatusRecruiting

PhasePhase 3

SponsorXenon Pharmaceuticals Inc.

Started2024-12-20

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

Protocol amendment history 1 change detected by DataLookout

2026-08-04

Trial sites expanded: 46 → 51 locations

Trial Details

NCT Number	NCT06775379
Lead Sponsor	Xenon Pharmaceuticals Inc.
Conditions	Major Depressive Disorder
Enrollment	450 participants
Start Date	2024-12-20
Primary Completion	2026-08 (estimated)
Study Completion	2026-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-03